

Financial news for MACK dated on 2020-05-08: Merrimack Pharmaceuticals Yesterday Reported Q1 EPS \$0.020 Up From \$(0.780) YoY

Financial news for MACK dated on 2020-04-02: Merrimack Pharma Reports Receipt Of \$2.25M Related To Closing Of Asset Sale For Preclinical Nanoliposome Programs To Celator Pharma

Financial news for MACK dated on 2020-03-24: The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test

Financial news for MACK dated on 2020-03-20: The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company

Financial news for MACK dated on 2020-03-19: Stocks That Hit 52-Week Lows On Thursday

Financial news for MACK dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest-stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for MACK dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for MACK dated on 2020-03-13: Stocks That Hit 52-Week Lows On Friday

Financial news for MACK dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for MACK dated on 2020-02-28: Stocks That Hit 52-Week Lows On Friday

Financial news for MACK dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for MACK dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for MACK dated on 2020-01-17: Stocks That Hit 52-Week Lows On Friday

Financial news for MACK dated on 2020-01-16: The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics

Financial news for MACK dated on 2019-12-27: Stocks That Hit 52-Week Lows On Friday

Financial news for MACK dated on 2019-12-20: The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering

Financial news for MACK dated on 2019-12-19: Stocks That Hit 52-Week Lows On Thursday

Financial news for MACK dated on 2019-12-04: 63 Biggest Movers From Yesterday

Financial news for MACK dated on 2019-12-03: Merrimack Declares Special Dividend Of ~\$0.50/Share

Financial news for MACK dated on 2019-12-03: Merrimack Receives \$5M Milestone Payment From Ipsen, Triggered By Ipsen's Decision To Progress Trial Evaluating ONIVYDE

Financial news for MACK dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for MACK dated on 2019-11-25: Stocks That Hit 52-Week Lows On Monday

Financial news for MACK dated on 2019-11-22: The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate

Financial news for MACK dated on 2019-11-21: Stocks That Hit 52-Week Lows On Thursday

Financial news for MACK dated on 2019-09-30: 52 Biggest Movers From Friday

Financial news for MACK dated on 2019-09-24: JFL Capital Reports Ended Campaign At Merrimack Pharma

Financial news for MACK dated on 2019-09-19: 2 Recent 13D Filings On Merrimack Pharma: Western Standard Shows 6.3% Stake, Newtyn Mgmt. Shows 8.8% Stake

Financial news for MACK dated on 2019-09-13: 58 Biggest Movers From Yesterday

Financial news for MACK dated on 2019-09-12: 71 Biggest Movers From Yesterday

Financial news for MACK dated on 2019-09-11: 48 Stocks Moving In Wednesday's Mid-Day Session

Financial news for MACK dated on 2019-08-22: JFL Capital Issues Letter Criticizing Board, Appoints New Nominees

Financial news for MACK dated on 2019-08-16: Merrimack Pharma To Reschedule 2019 Annual Shareholder Meeting From Oct. 17, 2019 To Sept. 16, 2019

Financial news for MACK dated on 2019-07-25: UPDATE: Merrimack Special Dividend \$1.50/Share

Financial news for MACK dated on 2019-07-25: Merrimack Declares \$20M Special Dividend

Financial news for MACK dated on 2019-07-16: Merrimack Pharmaceuticals Named New Long Idea At Seven Corners Capital, Firm Sets \$10.50 Price Target And Sees 84% Upside; Calls Stock ' Relatively Safe Pharma Play with Significant Upside'

Financial news for MACK dated on 2019-07-01: Merrimack Pharmaceuticals President, CEO And Director Richard Peters Resigned From Each Position As Of June 28, 2019

Financial news for MACK dated on 2019-06-24: Merrimack Pharma 8-K Shows Amendment For Asset Purchase Deal To Extend Closing Date For Transaction From Jun. 24, 2019 To Jun. 28, 2019

Financial news for MACK dated on 2019-05-31: The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

Financial news for MACK dated on 2019-05-30: Merrimack Pharma To Issue Near-Term Special Dividend Between \$16.9M-\$18.9M If Asset Sale To 14ner Oncology Closes, Between \$13.4M-\$15.4M If Asset Sale Does Not Successfully Close

Financial news for MACK dated on 2019-05-30: Merrimack Pharma Reports Completion Of Strategic Review, Will Implement Series Of Measures To Extend Co.'s Cash Runway Into 2027; 100 Potential Partners Were Contacted, Co. Will Not Move Forward With Any Of Them

Financial news for MACK dated on 2019-05-10: Merrimack Pharmaceuticals Q1 EPS \$(0.78) Up From \$(1.33) YoY

Financial news for MACK dated on 2019-04-30: Merrimack Pharma 8-K Shows Co. Board Committed To Implement Reduction In Headcount Affecting 13 Employees For Clinical Organization Following Discontinuation Of MM-310 Development

Financial news for MACK dated on 2019-04-08: 54 Biggest Movers From Friday

Financial news for MACK dated on 2019-04-05: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for MACK dated on 2019-04-05: Merrimack Pharmaceuticals shares are trading higher after the company discontinued development of its MM-310 after the safety report showed Phase 1 study was unable to reach optimal therapeutic index.

Financial news for MACK dated on 2019-04-05: 24 Stocks Moving In Friday's Pre-Market Session

Financial news for MACK dated on 2019-04-05: The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership

Financial news for MACK dated on 2019-04-04: Merrimack Discontinues Development Of MM-310 After Safety Update Showed Phase 1 Study Was Unable To Reach Optimal Therapeutic Index; Co. Plans To Reduce Workforce Reflective Of Narrowed Preclinical Development Pipeline

Financial news for MACK dated on 2018-11-07: Merrimack Pharmaceuticals Earlier Announced Restructuring Which Includes Workforce Reduction Of Approximately 60%

Financial news for MACK dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for MACK dated on 2018-11-07: Merrimack Pharmaceuticals, Inc. Q3 EPS From Continuing Operations \$(0.92)

Financial news for MACK dated on 2018-11-07: Merrimack Pharmaceuticals, Inc. Q3 EPS \$0.30 MAY Not Compare To \$(0.27) Estimate

Financial news for MACK dated on 2018-11-06: Merrimack Pharmaceuticals Q3 Earnings Preview

Financial news for MACK dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for MACK dated on 2018-10-22: 58 Biggest Movers From Friday

Financial news for MACK dated on 2018-10-19: Mid-Afternoon Market Update: NASDAQ Turns Lower; Bank OZK Shares Plummet

Financial news for MACK dated on 2018-10-19: 42 Stocks Moving In Friday's Mid-Day Session

Financial news for MACK dated on 2018-10-19: Mid-Day Market Update: Skechers Rises On Upbeat Earnings; Merrimack Pharmaceuticals Shares Slide

Financial news for MACK dated on 2018-10-19: Merrimack's String of Failures Continues With Lung Cancer Study Shelved After Midstage Trials

Financial news for MACK dated on 2018-10-19: Mid-Morning Market Update: Markets Open Higher; Procter & Gamble Profit Tops Estimates

Financial news for MACK dated on 2018-10-19: Merrimack Shares are trading lower after the company announced it would discontinue its Phase 2 SHERLOC study due to 'futility.'

Financial news for MACK dated on 2018-10-19: Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with NSCLC Due to Futility

Financial news for MACK dated on 2018-10-12: Stocks Which Set New 52-Week Low Yesterday, October 11th

Financial news for MACK dated on 2018-09-20: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for MACK dated on 2018-09-20: Merrimack Receives \$5M Milestone Payment from Shire Triggered By The Sale Of ONIVYDE In The First Non-European, Non-Asian Country Pursuant To The Terms Of Merrimack's Asset Sale To Ipsen In 2017

Financial news for MACK dated on 2018-09-06: Merrimack Reports Completion Of Enrollment In Randomized Phase 2 SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer

Financial news for MACK dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for MACK dated on 2018-08-07: Merrimack Pharmaceuticals Q2 EPS \$(1.33) Misses \$(1.28) Estimate

Financial news for MACK dated on 2018-07-10: Former Akebia and Merrimack Pharmaceuticals Employees Convicted of Insider Trading

Financial news for MACK dated on 2018-07-02: Merrimack Secures \$25M Debt Facility With Hercules Capital

Financial news for MACK dated on 2018-06-27: Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading

Financial news for MACK dated on 2018-06-26: 10 Biggest Price Target Changes For Tuesday

Financial news for MACK dated on 2018-06-26: Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results

Financial news for MACK dated on 2018-06-26: Baird Maintains Neutral on Merrimack Pharmaceuticals, Lowers Price Target to \$7

Financial news for MACK dated on 2018-06-26: 44 Biggest Movers From Yesterday

Financial news for MACK dated on 2018-06-25: Mid-Afternoon Market Update: NASDAQ Down Over 2.5%; Xerium Technologies Shares Spike Higher

Financial news for MACK dated on 2018-06-25: 36 Stocks Moving In Monday's Mid-Day Session

Financial news for MACK dated on 2018-06-25: Mid-Day Market Update: Dow Falls 350

Points; Merrimack Pharmaceuticals Shares Plummet

Financial news for MACK dated on 2018-06-25: Mid-Morning Market Update: Markets Open Lower; Carnival Cuts Profit Forecast

Financial news for MACK dated on 2018-06-25: JP Morgan Downgrades Merrimack Pharmaceuticals to Underweight

Financial news for MACK dated on 2018-06-25: Merrimack Plummets 30% After Pancreatic Cancer Drug Doesn't Meet Endpoints

Financial news for MACK dated on 2018-06-25: Merrimack Pharma Shares Down 34.3% Premarket After Phase 2 Trial Of MM-141 For Pancreatic Cancer Did Not Meet Primary Or Secondary Endpoints, Company Ceases Development Of MM-141

Financial news for MACK dated on 2018-06-25: Merrimack Pharma Phase 2 Trial Does Not Meet primary or Secondary Endpoints, Company Ceases Development of MM-141

Financial news for MACK dated on 2018-06-25: Merrimack Pharma Halted, News Pending

Financial news for MACK dated on 2018-06-13: Merrimack Pharma Shares Resume Trade, Now Up ~17% At \$10.23

Financial news for MACK dated on 2018-06-13: Merrimack Pharma Shares Halted On Circuit Breaker Up 15.1%

Financial news for MACK dated on 2018-06-13: UPDATE: Merrimack Pharma Shares Spike ~17% Over Last Few Mins., Now Up 15% For Session; Not Yet Seeing News To Justify Price Spike

Financial news for MACK dated on 2018-06-13: Merrimack Pharmaceuticals Option Alert: Jul 20 \$10 Calls at the Ask: 1100 @ \$0.85 vs 16 OI; Earnings 8/8 Before Open [est] Ref=\$8.86

Financial news for MACK dated on 2018-06-13: Merrimack Shares Spike To High Of \$9.27, Now Up ~4.6% At \$9.21/Share

Financial news for MACK dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for MACK dated on 2018-05-29: Merrimack Pharmaceuticals Awarded U.S. Patent For Bi-Specific Fusion Proteins

Financial news for MACK dated on 2018-05-08: Merrimack Pharmaceuticals Q1 EPS \$(1.33) Misses \$(1.16) Estimate

Financial news for MACK dated on 2018-04-19: 27 Stocks Moving In Thursday's Pre-Market Session

Financial news for MACK dated on 2018-03-26: 42 Biggest Movers From Friday

Financial news for MACK dated on 2018-03-13: 46 Biggest Movers From Yesterday

Financial news for MACK dated on 2018-03-12: Merrimack Pharmaceuticals Shares Down 10.1% After Co. Earlier Reported Q4 Loss Wider Than Expected

Financial news for MACK dated on 2018-03-12: Mid-Afternoon Market Update: BlueLinx Surges On Cedar Creek Acquisition; Anthera Pharmaceuticals Shares Plunge

Financial news for MACK dated on 2018-03-12: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for MACK dated on 2018-03-12: Merrimack Reports Q4 EPS \$(0.89) vs \$(0.28) Est.

Financial news for MACK dated on 2018-03-12: Earnings Scheduled For March 12, 2018

Financial news for MACK dated on 2018-03-11: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for MACK dated on 2018-02-26: Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer

Financial news for MACK dated on 2017-12-27: 6 Stocks Moving In Wednesday's After-Hours Session

Financial news for MACK dated on 2017-11-08: Merrimack Reports Q3 EPS From Continuing Operations \$(0.40) vs \$(1.88) Est.

Financial news for MACK dated on 2017-10-30: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for MACK dated on 2017-10-30: A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Consumer Spending Data

Financial news for MACK dated on 2017-10-30: Merrimack Receives Orphan Drug Designation from the FDA for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer

Financial news for MACK dated on 2017-10-10: 12 Stocks Moving In Tuesday's After-Hours Session

Financial news for MACK dated on 2017-10-10: Merrimack Announces Settlement of Convertible Note Litigation, Will Pay Plaintiffs \$0.90 per \$1 of Convertible Notes, Commence Tender Offer To Acquire All Remaining Convertible Notes At That Rate Plus Accrued Interest

Financial news for MACK dated on 2017-08-31: Merrimack Pharma Reports Date For 1-for-10 Reverse Split: Effective Sept. 6, 2017

Financial news for MACK dated on 2017-08-14: Merrimack Announces Jean Franchi CFO

Financial news for MACK dated on 2017-08-11: Merrimack Pharmaceuticals Holding Shareholder Meeting Today

Financial news for MACK dated on 2017-08-09: Merrimack Q2 EPS \$(0.03) vs \$(0.14) Est.

Financial news for MACK dated on 2017-05-25: Merrimack Announces Resignation Of CFO Dr. Yasir Al-Wakeel

Financial news for MACK dated on 2017-05-10: Merrimack Sees Receiving Up to \$33M in Net Milestone Payments within Its Cash Runway

Financial news for MACK dated on 2017-05-10: Merrimack Pharma Reports Q1 EPS \$(0.23) vs \$(0.11) Est.

Financial news for MACK dated on 2017-04-06: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for MACK dated on 2017-04-05: Merrimack Declares \$1.06 Special Dividend

Financial news for MACK dated on 2017-04-03: Merrimack To Return \$140M To Stockholders Through Special Cash Dividend

Financial news for MACK dated on 2017-04-03: Merrimack Launches New Focused Research & Clinical Co., Will Prioritize MM-121, MM-141 and MM-310 As Lead Pipeline Candidates

Financial news for MACK dated on 2017-03-30: Merrimack Stockholders Approve Sale of ONIVYDE and Generic DOXIL to Ipsent For Up To \$1.025B

Financial news for MACK dated on 2017-03-23: Merrimack Begins Phase 1 Study of MM-310 in Solid Tumors

Financial news for MACK dated on 2017-03-16: Merrimack Shares Spike to Session Highs, Now Up 6% as Traders Circulating Unconfirmed Rehashed Takeover Chatter of Shire Interest

Financial news for MACK dated on 2017-03-01: Merrimack Reports Q4 EPS \$(0.25) vs \$(0.21) Est., Sales \$61.24M vs \$50.4M Est.

Financial news for MACK dated on 2017-02-03: Benzinga's Option Alert Recap From February 3

Financial news for MACK dated on 2017-02-03: Option Alert: Merrimack Pharm Mar 4.0 Calls Sweep: 500 @ ASK \$0.15: 1000 traded vs 1871 OI: Earnings 2/23 After Close (est) \$3.14 Ref

Financial news for MACK dated on 2017-01-18: Merrimack Names Dr. Richard Peters CEO

Financial news for MACK dated on 2017-01-10: Merrimack Pharma Is Taking Steps In The Right Direction

Financial news for MACK dated on 2017-01-09: Mid-Morning Market Update: Markets Mostly Lower; Global Payments Earnings Beat Views

Financial news for MACK dated on 2017-01-09: 15 Stocks Moving In Monday's Pre-Market

Session

Financial news for MACK dated on 2017-01-09: The Market In 5 Minutes: Earnings Results, Conferences, Trump And More

Financial news for MACK dated on 2017-01-09: A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Fed Speakers

Financial news for MACK dated on 2017-01-09: Wall Street's M&A Chatter From January 6-8

Financial news for MACK dated on 2017-01-08: Merrimack Completes Previously Announced Strategic Pipeline Review

Financial news for MACK dated on 2017-01-08: Merrimack Pharmaceuticals Confirms Sale of Onivyde, Generic Version of Doxil to Ipsen for Up to \$1.025B

Financial news for MACK dated on 2017-01-08: Merrimack Near Deal to Sell Onivyde, Doxil to France's Ipsen for ~\$1B; Deal Could be Announced Monday -Reuters

Financial news for MACK dated on 2017-01-03: Option Alert: Merrimack Pharma Feb 6.0 Calls Sweep: 989 @ ASK \$0.15: 989 traded vs 209 OI: Earnings 2/23 After Close (est) \$4.04 Ref

Financial news for MACK dated on 2016-12-21: Mid-Afternoon Market Update: Crude Oil Down 1.5%; Merus Shares Spike Higher

Financial news for MACK dated on 2016-12-21: 15 Biggest Mid-Day Losers For Wednesday

Financial news for MACK dated on 2016-12-21: Mid-Day Market Update: InvenSense Climbs After Acquisition News; Merrimack Shares Drop

Financial news for MACK dated on 2016-12-21: Mid-Morning Market Update: Markets Edge Lower; Finish Line Misses Q3 Expectations

Financial news for MACK dated on 2016-12-21: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MACK dated on 2016-12-21: Merrimack Pharmaceuticals -11.555 @ \$4.75; Co Stopping Phase 2 HERMIONE study of MM-302

Financial news for MACK dated on 2016-12-21: A Peek Into The Markets: U.S. Stock Futures Flat Ahead Of Existing-Home Sales Report

Financial news for MACK dated on 2016-12-21: Merrimack Stops Phase 2 Study Of Breast Cancer Drug, Shares Lose 20%

Financial news for MACK dated on 2016-12-21: Merrimack Decides to Stop Phase 2 HERMIONE study of MM-302

Financial news for MACK dated on 2016-11-29: Vetr Upgrades Merrimack Following Earnings, Licensing Rumors

Financial news for MACK dated on 2016-11-11: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for MACK dated on 2016-11-10: The Market In 5 Minutes: Retail Earnings Come Into Focus

Financial news for MACK dated on 2016-11-10: Wall Street's M&A Chatter From November 10

Financial news for MACK dated on 2016-11-09: Merrimack Pharmaceuticals Reports Q3 EPS \$(0.23) vs. Est. \$(0.27), Rev. \$28M vs. Est. \$39M

Financial news for MACK dated on 2016-11-09: Option Alert: MACK Nov16 6.0 Calls Sweep: 1620 @ ASK \$0.55: 1692 traded vs 1424 OI: Earnings today After Close \$5.78 Ref

Financial news for MACK dated on 2016-11-09: Merrimack Reviews Strategic Alternatives, Possible Asset Sale

Financial news for MACK dated on 2016-10-31: Merrimack Reports Acceptance for Review of ANDA filed by Actavis for Generic Doxorubicin Hydrochloride Liposome Injection

Financial news for MACK dated on 2016-10-18: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for MACK dated on 2016-10-18: 16 Stocks Moving In Tuesday's Pre-Market Session

Financial news for MACK dated on 2016-10-18: Shire Granted EU Marketing Authorization of Onivyde in Combination With 5-Fluorouracil and Leucovorin for Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy

Financial news for MACK dated on 2016-10-12: Merrimack Pharma Shares Quiet, Remain Near Session Lows; Hearing Agora Newsletter Recommendation Suggests Name Could Be 'Prime Candidate' for Short Squeeze

Financial news for MACK dated on 2016-10-11: 14 Stocks Moving In Tuesday's Pre-Market Session

Financial news for MACK dated on 2016-10-11: Merrimack Pharmaceuticals Reports Overall Survival and PFS Benefit Of ONIVYDE For Pancreatic Cancer Patients

Financial news for MACK dated on 2016-10-07: 4 Reasons JPMorgan Just Downgraded Merrimack Pharmaceuticals

Financial news for MACK dated on 2016-10-07: 18 Biggest Mid-Day Losers For Friday

Financial news for MACK dated on 2016-10-07: Merrimack Pharmaceuticals Falls Back To Support Following JPMorgan Downgrade

Financial news for MACK dated on 2016-10-07: Benzinga's Top Downgrades

Financial news for MACK dated on 2016-10-07: JP Morgan Downgrades Merrimack Pharmaceuticals to Neutral

Financial news for MACK dated on 2016-10-07: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for MACK dated on 2016-10-03: 10 Biggest Mid-Day Losers For Monday

Financial news for MACK dated on 2016-10-03: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for MACK dated on 2016-10-03: Merrimack Pharma Shares Resume Trade, Now Down 9%

Financial news for MACK dated on 2016-10-03: Merrimack Pharmaceuticals to Resume Trading @7:45 AM ET

Financial news for MACK dated on 2016-10-03: UPDATE: Merrimack Names Gary Crocker Interim CEO

Financial news for MACK dated on 2016-10-03: Merrimack To Reduce Workforce By 22%, Eliminating \$200M In Costs Over Next 2 Years; Accepts CEO Robert Mulroy's Resignation Effective Immediately

Financial news for MACK dated on 2016-10-03: Merrimack Pharmaceuticals Halted; Pending News

Financial news for MACK dated on 2016-10-03: Watch These Huge Call Purchases In Monday Trade

Financial news for MACK dated on 2016-09-30: Option Alert: MACK Oct16 7.0 Calls Sweep: 1865 @ ASK \$0.35: 2366 traded vs 785 OI: Earnings 11/14 \$6.34 Ref

Financial news for MACK dated on 2016-09-28: Merrimack To Present Final NAPOLI-1 Phase 3 Results At European Society For Medical Oncology 2016 Congress

Financial news for MACK dated on 2016-09-27: Watch These 7 Huge Call Purchases In Tuesday Trade

Financial news for MACK dated on 2016-09-26: Option Alert: MACK Oct16 6.0 Calls: 1193 @ ASK \$0.95: 1809 traded vs 2457 OI: Earnings 11/14 \$6.57 Ref

Financial news for MACK dated on 2016-09-23: 20 Stocks Which Rallied Three Days On Increasing Volume

Financial news for MACK dated on 2016-09-22: Technical Alert - Merrimack Pharmaceuticals On Two-Day Run

Financial news for MACK dated on 2016-08-19: Expect Merrimack Pharma Shares To Be Range-Bound For The Near Term

Financial news for MACK dated on 2016-08-19: Benzinga's Top Initiations

Financial news for MACK dated on 2016-08-19: BTIG Research Initiates Coverage on Merrimack Pharmaceuticals at Neutral

Financial news for MACK dated on 2016-08-04: Merrimack Reports Q2 EPS \$(0.40) vs. Est. \$(0.33), Rev. \$33.6M vs. Est. \$30.9M

Financial news for MACK dated on 2016-07-29: Merrimack Pharma Shares Spike Higher as Hearing CNBC's Jon Najarian Has Purchased Stock for His Model Portfolio

Financial news for MACK dated on 2016-07-28: Option Alert: MACK Aug16 6.0 Calls Sweep: 1840 @ ASK \$0.25: 2032 traded vs 920 OI: Earnings 8/4 After Close \$5.52 Ref

Financial news for MACK dated on 2016-07-25: 13 Stocks Moving In Monday's Pre-Market Session

Financial news for MACK dated on 2016-07-25: Merrimack Announces ONIVYDE Regimen Receives Positive CHMP Opinion in EU

Financial news for MACK dated on 2016-07-06: Merrimack Pharma Reports FDA Granted Fast Track Designation for MM-121 in Non-Small Cell Lung Cancer

Financial news for MACK dated on 2016-06-30: NAPOLI-1 Data Shows ONIVYDE Regimen Maintains Quality of Life While Improving Overall Survival in Patients with Metastatic Pancreatic Cancer

Financial news for MACK dated on 2016-06-21: Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data During ESMO 18th World Congress On Gastrointestinal Cancer

Financial news for MACK dated on 2016-06-06: Merrimack Pharmaceuticals Reports Potential Broad Effect Of MM-151 Across EGFR-Refractory & Naive Populations

Financial news for MACK dated on 2016-05-26: Baird Initiates Coverage on Merrimack Pharmaceuticals at Neutral

Financial news for MACK dated on 2016-05-19: Merrimack, Baxalta Report Initiation of Phase 1 Study of MM-151 in Combo with ONIVYDE Regimen for Metastatic Colorectal Cancer

Financial news for MACK dated on 2016-05-18: Merrimack Will Present Extensive Oncology Pipeline at ASCO

Financial news for MACK dated on 2016-05-17: UPDATE: Merrimack Says Data from MM-121 Phase 2 Shows 'presence of heregulin may increase risk of progression on exemestane alone in 45% of breast cancer patients tested'

Financial news for MACK dated on 2016-05-17: Merrimack Reports Expanded Analysis Of Seribantumab Reduced Risk of Death In 50% Of HER2-Negative Hormone Receptor Positive Breast Cancer Patients

Financial news for MACK dated on 2016-05-02: Merrimack Pharma Reports Q1 EPS \$(0.33) Vs Est \$(0.38), Sales \$21.3M Vs Est \$24.16M

Financial news for MACK dated on 2016-04-21: Merrimack Pharma Launches MM-310 at AACR

Financial news for MACK dated on 2016-04-14: Leica Biosystems and Merrimack Pharmaceuticals to Collaborate on Development of a Heregulin Companion Diagnostic for Seribantumab

Financial news for MACK dated on 2016-03-24: Merrimack Reports Inclusion of ONIVYDE as Category 1 Treatment Option in '16 NCCN Guidelines for Pancreatic Adenocarcinoma

Financial news for MACK dated on 2016-03-17: Dir Porter Buys 5,000 Shares of Merrimack Pharmaceuticals @\$7.65/Share -Form 4

Financial news for MACK dated on 2016-03-10: Director Porter Buys 10,000 Shars of Merrimack Pharmaceuticals @\$7.09/Share -Form 4

Financial news for MACK dated on 2016-03-04: Director Porter Buys 15,000 Shares of Merrimack Pharmaceuticals

Financial news for MACK dated on 2016-03-02: Dir Porter Buys 20,000 Shares Of Merrimack Pharmaceuticals @\$6.11/Share -Form 4

Financial news for MACK dated on 2016-03-01: VP McClements Buys 2,000 SharesOf Merrimack Pharmaceuticals @\$5.72/Share -Form 4

Financial news for MACK dated on 2016-02-29: Director Lee Buys 35,000 Shares Of Merrimack Pharmaceuticals @\$5.50/Share -Form 4

Financial news for MACK dated on 2016-02-25: Merrimack Reports Q4 EPS \$(0.41) vs. Est. \$(0.31), Rev. \$21.4M vs. Est. \$26.58M

Financial news for MACK dated on 2016-01-12: Merrimack Shares Falling

Financial news for MACK dated on 2015-12-22: Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration

Financial news for MACK dated on 2015-11-23: Merrimack and Baxalta Announce Publication of the ONIVYDE(tm) (irinotecan liposome injection) NAPOLI-1 Study in The Lancet

Financial news for MACK dated on 2015-11-09: Merrimack Pharma Reports Q3 EPS (\$0.38) Vs Est (\$0.40), Sales \$16.4M Vs Est \$14.04M

Financial news for MACK dated on 2015-10-23: PharmaEngine Announces FDA Approves Merrimack's ONIVYDE

Financial news for MACK dated on 2015-10-22: Merrimack Confirms U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer

Financial news for MACK dated on 2015-10-22: FDA Had Granted Priority Review, Orphan Drug Designations for Merrimack's Onivyde

Financial news for MACK dated on 2015-10-22: FDA OK's Merrimack's Onivyde in Combination with Fluorouracil, Leucovorin; Approves Merrimack Pharma's Onivyde for Advanced Pancreatic Cancer

Financial news for MACK dated on 2015-10-22: Merrimack Gets FDA Approval for Advanced Pancreatic Cancer Treatment -Reuters

Financial news for MACK dated on 2015-10-22: Merrimack Pharma. Shares Halted News Pending

Financial news for MACK dated on 2015-10-06: Merrimack Pharma Could Have FDA Approval Coming; These Analysts Are Buying

Financial news for MACK dated on 2015-08-20: 10 Biotech Stocks With Catalysts Coming Soon

Financial news for MACK dated on 2015-08-13: Merrimack Pharmaceuticals Director Porter Buys 20,000 Shares @\$10.16/Share -Form 4

Financial news for MACK dated on 2015-08-12: Oppenheimer Assumes Merrimack Pharmaceuticals at Outperform, Announces \$13.00 PT

Financial news for MACK dated on 2015-08-10: Merrimack Pharma. Reports Q2 EPS \$(0.21) vs. Est. \$(0.31)

Financial news for MACK dated on 2015-08-06: Merrimack Pharma Names Dr. Yasir Al-Wakeel CFO

Financial news for MACK dated on 2015-06-30: Option Alert: Merrimack Jul \$13 Call Sweep; 1165 Contracts @Ask @\$0.40

Financial news for MACK dated on 2015-06-25: US Stock Futures Surge Ahead Of Jobless Claims

Financial news for MACK dated on 2015-06-25: U.S. FDA Grants Priority Review for MM-398 New Drug Application

Financial news for MACK dated on 2015-06-15: Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO Of GE Healthcare, To Board

Financial news for MACK dated on 2015-06-11: Merrimack Pharmaceuticals Reports Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer

Financial news for MACK dated on 2015-06-10: Merrimack Forms A Major Topping Pattern

Financial news for MACK dated on 2015-06-01: Merrimack Pharmaceuticals Reports Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma

Financial news for MACK dated on 2015-06-01: PharmaEngine Announces Filing NDA of MM-398 to Taiwan FDA as Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer

Financial news for MACK dated on 2015-05-15: Merrimack Pharmaceuticals Director Porter Buys 8,284 Shares @\$11.79/Share -Form 4

Financial news for MACK dated on 2015-05-13: Benzinga's Top Initiations

Financial news for MACK dated on 2015-05-13: Guggenheim Securities Initiates Merrimack Pharmaceuticals With Buy

Financial news for MACK dated on 2015-05-13: Guggenheim Securities Initiates Coverage on Merrimack Pharmaceuticals at Buy, Announces \$15.00 PT

Financial news for MACK dated on 2015-05-07: Merrimack Pharma Earlier Reported Q1 Loss of \$0.32/Share vs Loss of \$0.28/Share Est.

Financial news for MACK dated on 2015-05-05: Merrimack Pharmaceuticals Reports Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer

Financial news for MACK dated on 2015-05-04: Baxter Bioscience, Merrimack Pharma Report Filing of European Approval for MM-398

Financial news for MACK dated on 2015-05-02: These 10 Stocks Could Move Big On Monday

Financial news for MACK dated on 2015-04-27: PharmaEngine Announces Merrimack Completed MM-398 NDA Submission to U.S. FDA

Financial news for MACK dated on 2015-04-27: Merrimack Pharma, Baxter BioScience Report Closing of NDA Submission to FDA for MM-398 for Treatment of Post-Gemcitabine Metastatic Pancreatic Cancer

Financial news for MACK dated on 2015-04-21: First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients

Financial news for MACK dated on 2015-04-21: Mizuho Securities Maintains Buy on Merrimack Pharmaceuticals, Raises PT to \$16.00

Financial news for MACK dated on 2015-04-20: Merrimack Pharma Reports Final Clinical Results for MM-302 Phase 1 Study

Financial news for MACK dated on 2015-04-10: Option Alert: Merrimack Pharma May \$13 Call; 3260 Contract Trade at Ask @\$0.80; Now \$12.39

Financial news for MACK dated on 2015-04-01: QuickLogic, Sonic Corp, BioMarin Pharmaceutical Lead Wednesday's After-Hours Movers

Financial news for MACK dated on 2015-04-01: Hearing Merrimack CEO Coming Up on CNBC After 2:00 PM ET

Financial news for MACK dated on 2015-03-24: Merrimack Pharmaceuticals Director Porter Buys 5,000 Shares @\$11.77/Share -Form 4

Financial news for MACK dated on 2015-03-10: After-Hours Movers Led By Pioneer Energy, Weibo & Habit Restaurants

Financial news for MACK dated on 2015-02-26: Merrimack Pharma Reports Q4 EPS -\$0.09 Vs Est -\$0.19; Expects to Start Clinical Trials of MM-398, MM-141 in Front-Line Pancreatic Cancer in 2015; Expects Completion of NDA Submission to FDA for MM-398 in Late 1Q/Early 2Q 2015

Financial news for MACK dated on 2015-02-19: Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial MM-121

Financial news for MACK dated on 2015-01-20: Merrimack Pharma Offers Added Date Showing Support for MM-141, MM-151 for Pancreatic, Colorectal Cancer, Respectively

Financial news for MACK dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

Financial news for MACK dated on 2014-12-23: Merrimack Pharmaceuticals Director Lee Buys 20,000 Shares @\$10.23/Share -Form 4

Financial news for MACK dated on 2014-12-04: Merrimack Pharmaceuticals Director Porter Buys 8,000 Shares @\$8.71/Share -Form 4

Financial news for MACK dated on 2014-11-19: Merrimack Pharma Reports FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer

Financial news for MACK dated on 2014-11-18: Merrimack Pharmaceuticals Director Porter Buys 5,000 Shares @\$8.29/Share -Form 4

Financial news for MACK dated on 2014-11-14: Merrimack Pharmaceuticals Chairman Crocker Buys 14,390 Shares @\$8.47/Share -Form 4

Financial news for MACK dated on 2014-11-13: Merrimack Pharmaceuticals Director Porter Buys 40,000 Shares @\$8.37/Share -Form 4

Financial news for MACK dated on 2014-11-10: Merrimack Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.27) vs \$(0.12) Est; Revenue of \$28.0M vs \$21.79M Est

Financial news for MACK dated on 2014-11-06: Merrimack Pharmaceuticals Announces Initiation Of Phase 1 Clinical Study Of MM-398 For Brain Cancer

Financial news for MACK dated on 2014-11-05: FDA Grants Orphan Drug Designation To Merrimack Pharmaceuticals' MM-141 For The Treatment of Pancreatic Cancer

Financial news for MACK dated on 2014-10-06: Top 5 Biotech Stocks Over The Past Year

Financial news for MACK dated on 2014-09-30: Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening The Finding That MM-121 Increases Progression Free Survival In Patients With Biomarker Positive Metastatic Breast Cancer

Financial news for MACK dated on 2014-09-26: PharmaEngine, Merrimack Amend MM-398 License Agreement

Financial news for MACK dated on 2014-09-24: Stocks Gain While Dollar Reaches Highest Level Since 2010

Financial news for MACK dated on 2014-09-24: Dow Jumps 170 Points; Bed Bath & Beyond Shares Rise On Upbeat Results

Financial news for MACK dated on 2014-09-24: U.S. Stocks Rise; Accenture Shares Decline On Weak Forecast

Financial news for MACK dated on 2014-09-24: Markets Edge Lower; KB Home Posts Downbeat Results

Financial news for MACK dated on 2014-09-24: Morning Market Movers

Financial news for MACK dated on 2014-09-24: Benzinga's Top #PreMarket Gainers

Financial news for MACK dated on 2014-09-24: Merrimack Shares Rise 21% Premarket on Licensing Deal with Baxter

Financial news for MACK dated on 2014-09-24: Baxter And Merrimack Pharmaceuticals Enter Into Exclusive Ex-U.S. Licensing Agreement to Develop And Commercialize Novel Cancer Compound MM-398

Financial news for MACK dated on 2014-09-08: Cantor Initiates Coverage on Six Pharma Stocks, Each with Buy

Financial news for MACK dated on 2014-09-08: 3 Cheap Biotech Stocks Analysts Love: Ohr Pharmaceutical Inc, Merrimack & Amicus

Financial news for MACK dated on 2014-08-11: Merrimack Pharma Announces Initiation of MM-302 Study

Financial news for MACK dated on 2014-08-11: Merrimack Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.17) Which May Not Compare \$(0.30) Est; Revenue of \$27.80M Which May Not Compare \$11.02M Est

Financial news for MACK dated on 2014-07-03: 4 Biotech Stocks Worth A Look Ahead Of FDA Approvals

Financial news for MACK dated on 2014-06-26: Sub \$10 Stocks With High Institutional & Insider Ownership: Investment Idea Of The Day

Financial news for MACK dated on 2014-06-25: UPDATE: Merrimack's NAPOLI-1 Study of MM-398 Showed Significant Improvement in Overall Survival; Co Plans NDA in '14

Financial news for MACK dated on 2014-06-25: Merrimack Pharma Announces Positive Results From Phase 3 NAPOLI-1 Study

Financial news for MACK dated on 2014-06-19: After-Hours Movers: FDO, APP Higher, SWHC, ORCL, MACK Lower

Financial news for MACK dated on 2014-06-19: Merrimack Pharmaceuticals Reaches Agreement With Sanofi, Regains Rights to Develop And Commercialize MM-121

Financial news for MACK dated on 2014-06-17: Merrimack Pharma Will Present Added Data Results in Phase 3 NAPOLI-q Study at ESMO

Financial news for MACK dated on 2014-06-04: Benzinga's Top #PreMarket Gainers

Financial news for MACK dated on 2014-06-02: Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting

Financial news for MACK dated on 2014-06-02: Merrimack Pharma Has Identified Heregulin as Patient Response Biomarker for MM-121

Financial news for MACK dated on 2014-05-22: Merrimack Pharmaceuticals Chairman Crocker Buys 4,000 Shares @\$6.69/Share -Form 4

Financial news for MACK dated on 2014-05-20: Merrimack Pharmaceuticals Chairman Crocker Buys 9,400 Shares @\$6.68/Share -Form 4

Financial news for MACK dated on 2014-05-16: Merrimack Pharmaceuticals Director Porter Buys 15,000 Shares @\$6.49/Share -Form 4

Financial news for MACK dated on 2014-05-09: Merrimack Pharmaceuticals Director Nash Buys 15,000 Shares @\$6.79/Share -Form 4

Financial news for MACK dated on 2014-05-07: Merrimack Pharmaceuticals Chairman Crocker Buys 17,500 Shares @\$6.89/Share -Form 4

Financial news for MACK dated on 2014-05-02: PharmaEngine, Merrimack, Announce MM-398 in Combination with 5-FU/LV Met Primary Endpoint of Overall Survival in Phase 3 Post-Gemcitabine Metastatic Pancreatic Cancer Study

Financial news for MACK dated on 2014-05-01: Market Wrap For May 1: Markets Mixed To Start The New Month

Financial news for MACK dated on 2014-05-01: Mid-Afternoon Market Update: Markets Turn Back As Meritor Hangs Onto Its Gains

Financial news for MACK dated on 2014-05-01: Mid-Day Market Update: Weight Watchers Shares Surge On Upbeat Results; JDS Uniphase Tumbles

Financial news for MACK dated on 2014-05-01: Cowen & Company Upgrades Merrimack Pharmaceuticals, Inc. to Outperform

Financial news for MACK dated on 2014-05-01: Mid-Morning Market Update: Markets Mixed; Viacom Posts Upbeat Earnings

Financial news for MACK dated on 2014-05-01: Morning Market Movers

Financial news for MACK dated on 2014-05-01: Benzinga's Top #PreMarket Gainers

Financial news for MACK dated on 2014-05-01: Merrimack Pharmaceuticals MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer

Financial news for MACK dated on 2014-04-08: Merrimack Announces Preliminary Data From Pilot Diagnostic Imaging Study of MM-398

Financial news for MACK dated on 2014-03-04: After-Hours Movers: BV, SWHC, AVAV, CTIC Moving Higher, HCI, BOBE, CHEF, THOR Lower

Financial news for MACK dated on 2014-03-04: Merrimack Pharma Files Mixed Securities Shelf Up to \$200M

Financial news for MACK dated on 2014-02-27: Merrimack Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.33) vs \$(0.29) Est

Financial news for MACK dated on 2014-02-18: Preclinical Study Results of Merrimack's MM-141 Published in Molecular Cancer Therapeutics

Financial news for MACK dated on 2013-12-13: Merrimack Announces Encouraging Clinical Data From Expanded Phase 1 Study of MM-302 for the Treatment of Advanced HER2-Positive Breast Cancer

Financial news for MACK dated on 2013-12-09: Director Quigley Buys 39,000 Shares of Merrimack Pharmaceuticals -Form 4

Financial news for MACK dated on 2013-12-02: Benzinga's Top #PreMarket Gainers

Financial news for MACK dated on 2013-11-26: Merrimack, Actavis Announce Nanotechnology Collaboration

Financial news for MACK dated on 2013-11-07: Merrimack Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.39) vs \$(0.31) Est; Revenue of \$6.86M vs \$15.45M Est

Financial news for MACK dated on 2013-10-30: Stocks Hitting 52-Week Lows

Financial news for MACK dated on 2013-10-30: Benzinga's Top #PreMarket Losers

Financial news for MACK dated on 2013-10-30: Merrimack Pharmaceuticals Announces Phase 2 Study Of MM-121 Misses Primary Endpoint

Financial news for MACK dated on 2013-08-29: PharmaEngine, Merrimack Achieve Patient Enrollment Goal in Phase III Metastatic Pancreatic Cancer Study of PEP02

Financial news for MACK dated on 2013-08-14: Stocks Hitting 52-Week Lows

Financial news for MACK dated on 2013-08-13: Merrimack Pharm Wins Orphan Drug Status for MM-111

Financial news for MACK dated on 2013-08-12: Benzinga's Top Pre-Market Gainers

Financial news for MACK dated on 2013-08-09: UPDATE: Bank of America Downgrades Merrimack Pharmaceuticals Following Series of Disappointing Updates

Financial news for MACK dated on 2013-08-09: Bank of America Downgrades Merrimack Pharmaceuticals, Inc. to Neutral, Lowers PO to \$6.00

Financial news for MACK dated on 2013-08-08: Cowen & Company Downgrades Merrimack Pharmaceuticals, Inc. to Market Perform

Financial news for MACK dated on 2013-08-08: Merrimack Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.31) vs \$(0.28) Est; Revenue of \$18.50M vs \$13.68M Est

Financial news for MACK dated on 2013-07-12: A Peek Into The Market Before The Trading Starts

Financial news for MACK dated on 2013-07-12: Merrimack Prices 5 Share Secondary at \$5.00/Share

Financial news for MACK dated on 2013-07-11: Market Wrap for Thursday, July 11: Market Jumps on Dovish Bernanke Comments

Financial news for MACK dated on 2013-07-11: Mid-Day Market Update: PriceSmart Drops On Downbeat Earnings, Alnylam Gains

Financial news for MACK dated on 2013-07-11: Mid-Morning Market Update: Markets Surge, Yum! Brands Posts Upbeat Profit

Financial news for MACK dated on 2013-07-10: Merrimack Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes

Financial news for MACK dated on 2013-06-25: Mizuho Securities Initiates Coverage on Merrimack Pharmaceuticals, Inc. at Buy, Announces \$12.00 PT

Financial news for MACK dated on 2013-05-13: Earnings Scheduled For May 13, 2013

Financial news for MACK dated on 2013-05-06: Stocks Hitting 52-Week Lows

Financial news for MACK dated on 2013-04-10: Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model

Financial news for MACK dated on 2013-02-01: Merrimack Pharma Files \$200M Mixed Securities Shelf

Financial news for MACK dated on 2012-10-12: Merrimack Pharmaceuticals Spokesperson Says No News Issued by Company to Account for Spike Earlier

Financial news for MACK dated on 2012-10-12: Merrimack Pharmaceuticals Spikes Higher

Financial news for MACK dated on 2012-10-03: Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)

Financial news for MACK dated on 2012-10-02: Merrimack Pharma Presents Positive Phase 1 Safety and Clinical Results for Cancer Drug

Financial news for MACK dated on 2012-09-27: Brean Murray Carret Initiated Coverage

on Merrimack Pharmaceuticals at Buy, Announced PT to \$12

Financial news for MACK dated on 2012-09-25: Benzinga Mid-Afternoon Market Update

Financial news for MACK dated on 2012-09-25: Benzinga Mid-Day Market Update

Financial news for MACK dated on 2012-09-25: Benzinga Mid-Morning Market Update

Financial news for MACK dated on 2012-09-25: Merrimack Pharma Down Over 20%; Lockup Expired Today

Financial news for MACK dated on 2012-09-25: Morning Market Losers

Financial news for MACK dated on 2012-09-21: Benzinga Mid-Afternoon Market Update

Financial news for MACK dated on 2012-09-21: Benzinga Mid-Day Market Update

Financial news for MACK dated on 2012-09-21: Benzinga Mid-Morning Market Update

Financial news for MACK dated on 2012-08-31: Benzinga's Top Initiations

Financial news for MACK dated on 2012-08-31: UPDATE: Bank of America Initiates Buy, \$13 PO on Merrimack Pharmaceuticals

Financial news for MACK dated on 2012-08-31: Bank of America Initiates Coverage on Merrimack Pharmaceuticals at Buy, Announces PO of \$13

Financial news for MACK dated on 2012-07-19: Merrimack Pharmaceuticals Receives Positive Mad Money/Jim Cramer Mention -CNBC

Financial news for MACK dated on 2012-05-08: UPDATE: Oppenheimer Initiates Coverage on Merrimack Pharmaceuticals

Financial news for MACK dated on 2012-05-08: UPDATE: J.P. Morgan Initiates Coverage on Merrimack Pharmaceuticals

Financial news for MACK dated on 2012-03-29: Merrimack Pharma IPO Opens for Trading at \$7, After Originally Pricing at \$7/Share

Financial news for MACK dated on 2012-03-29: From EARLIER: Merrimack Pharmaceuticals Announces Pricing of Initial Public Offering of 14.3M Shares at \$7.00